The Food and Drug Administration (FDA) has approved the HIV-1 medication ibalizumab-uiyk (Trogarzo, Theratechnologies Inc) for administration by intravenous push. Ibalizumab-uiyk, a long-acting ...
The new approval allows for the 2000mg loading dose to be administered as an IV push rather than a 30-minute IV infusion. The prescribing information for Trogarzo ® (ibalizumab-uiyk) has been updated ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
(RTTNews) - Theratechnologies Inc. (THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received FDA approval for the intravenous push mode ...
Intravenous (IV) therapy is administering fluids directly into a vein. It benefits treatment by enabling water, medication, blood, or nutrients to access the body faster through the circulatory system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results